CGEN (Compugen) Tariff Resilience Score: 6/10 (As of Jun. 30, 2026)


CGEN Compugen Ltd CGEN
60 GF Score
Price $2.16
GF Value $5.31
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Compugen Tariff Resilience Score?

Compugen CGEN +2.86% 60 Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus rates CGEN with a GF Score™ of 60/100 and a GF Value™ of $5.31 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,375 Biotechnology companies, Compugen ranks better than 76% on this metric.

Compugen has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Compugen has Compugen Ltd has moderate tariff exposure due to its international collaborations and partnerships. While it has some pricing power, the biotech sector's reliance on global supply chains poses risks. Historical impacts have been manageable, with some mitigation strategies in place.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Compugen might have Average Resilient.

Compugen  (NAS:CGEN) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Compugen Tariff Resilience Score Related Terms

CGEN vs VRTX, REGN, ALNY: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Compugen's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Compugen Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Compugen's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Compugen's Tariff Resilience Score falls into.


CGEN
60GF Score
Compugen Ltd CGEN
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Compugen (CGEN) has a Tariff Resilience Score of 6 as of Jun. 30, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Compugen ranks #330 out of 1375 companies in the Biotechnology industry, placing it in the top 24%.
Is Compugen's Tariff Resilience Score too high?
Compugen's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Compugen's value of 6 is 50% above this industry median. Based on the distribution chart, Compugen ranks #330 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Compugen has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Compugen's Tariff Resilience Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Compugen ranks #330 out of 1375 companies for Tariff Resilience Score. This places Compugen in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Compugen's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Compugen's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Compugen's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compugen stock overvalued right now?
Based on GuruFocus' analysis, Compugen (CGEN) is currently considered Possible Value Trap. The stock's GF Value™ is $5.31, compared to a current price of $2.16 — trading 59.3% below its estimated fair value. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Compugen's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Compugen (CGEN), the current Tariff Resilience Score is 6 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Compugen (CGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Compugen stock appears to be undervalued. The current stock price of $2.16 is trading 59.3% below its estimated GF Value™ of $5.31. GuruFocus considers Compugen to be Possible Value Trap.

Key valuation signals for CGEN:

  • Tariff Resilience Score: 6
  • GF Value™: $5.31 vs. price of $2.16 (59.3% below fair value)
  • GF Score™: 60/100 with 4 warning signs
  • Industry Position: 50% above the Biotechnology median (#330 of 1375)

No single metric tells the full story. See the CGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Compugen Business Description

Other Exchanges CGEN:Israel
Address 26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.
60GF Score

Get the complete analysis for CGEN

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.16
Price
$5.31
GF Value